Your browser doesn't support javascript.
loading
TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.
Ma, X Rosa; Prudencio, Mercedes; Koike, Yuka; Vatsavayai, Sarat C; Kim, Garam; Harbinski, Fred; Briner, Adam; Rodriguez, Caitlin M; Guo, Caiwei; Akiyama, Tetsuya; Schmidt, H Broder; Cummings, Beryl B; Wyatt, David W; Kurylo, Katherine; Miller, Georgiana; Mekhoubad, Shila; Sallee, Nathan; Mekonnen, Gemechu; Ganser, Laura; Rubien, Jack D; Jansen-West, Karen; Cook, Casey N; Pickles, Sarah; Oskarsson, Björn; Graff-Radford, Neill R; Boeve, Bradley F; Knopman, David S; Petersen, Ronald C; Dickson, Dennis W; Shorter, James; Myong, Sua; Green, Eric M; Seeley, William W; Petrucelli, Leonard; Gitler, Aaron D.
Afiliação
  • Ma XR; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Prudencio M; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Koike Y; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Vatsavayai SC; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Kim G; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Harbinski F; Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Briner A; Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
  • Rodriguez CM; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Guo C; Neurosciences Interdepartmental Program, Stanford University School of Medicine, Stanford, CA, USA.
  • Akiyama T; Maze Therapeutics, South San Francisco, CA, USA.
  • Schmidt HB; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Cummings BB; Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, Queensland, Australia.
  • Wyatt DW; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Kurylo K; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Miller G; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Mekhoubad S; Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
  • Sallee N; Maze Therapeutics, South San Francisco, CA, USA.
  • Mekonnen G; Maze Therapeutics, South San Francisco, CA, USA.
  • Ganser L; Maze Therapeutics, South San Francisco, CA, USA.
  • Rubien JD; Maze Therapeutics, South San Francisco, CA, USA.
  • Jansen-West K; Maze Therapeutics, South San Francisco, CA, USA.
  • Cook CN; Maze Therapeutics, South San Francisco, CA, USA.
  • Pickles S; Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, MD, USA.
  • Oskarsson B; Department of Biology, Johns Hopkins University, Baltimore, MD, USA.
  • Graff-Radford NR; Department of Biophysics, Johns Hopkins University, Baltimore, MD, USA.
  • Boeve BF; Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Knopman DS; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Petersen RC; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Dickson DW; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Shorter J; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Myong S; Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.
  • Green EM; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Seeley WW; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Petrucelli L; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Gitler AD; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Nature ; 603(7899): 124-130, 2022 03.
Article em En | MEDLINE | ID: mdl-35197626
ABSTRACT
A hallmark pathological feature of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the depletion of RNA-binding protein TDP-43 from the nucleus of neurons in the brain and spinal cord1. A major function of TDP-43 is as a repressor of cryptic exon inclusion during RNA splicing2-4. Single nucleotide polymorphisms in UNC13A are among the strongest hits associated with FTD and ALS in human genome-wide association studies5,6, but how those variants increase risk for disease is unknown. Here we show that TDP-43 represses a cryptic exon-splicing event in UNC13A. Loss of TDP-43 from the nucleus in human brain, neuronal cell lines and motor neurons derived from induced pluripotent stem cells resulted in the inclusion of a cryptic exon in UNC13A mRNA and reduced UNC13A protein expression. The top variants associated with FTD or ALS risk in humans are located in the intron harbouring the cryptic exon, and we show that they increase UNC13A cryptic exon splicing in the face of TDP-43 dysfunction. Together, our data provide a direct functional link between one of the strongest genetic risk factors for FTD and ALS (UNC13A genetic variants), and loss of TDP-43 function.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Demência Frontotemporal / Esclerose Lateral Amiotrófica Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Demência Frontotemporal / Esclerose Lateral Amiotrófica Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos